Equities Analysts Issue Forecasts for NAMS Q3 Earnings

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) – Investment analysts at HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for NewAmsterdam Pharma in a note issued to investors on Thursday, August 6th. HC Wainwright analyst L. Egana-Gorrono now expects that the company will post earnings per share of ($0.62) for the quarter, down from their prior estimate of ($0.58). The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q4 2026 earnings at ($0.28) EPS and FY2026 earnings at ($1.82) EPS.

Several other brokerages have also recently issued reports on NAMS. Jefferies Financial Group restated a “buy” rating and issued a $45.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. BMO Capital Markets started coverage on NewAmsterdam Pharma in a report on Monday, July 20th. They issued an “outperform” rating and a $58.00 price objective for the company. Finally, Royal Bank Of Canada lowered their target price on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $49.33.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS opened at $27.62 on Monday. The firm’s 50 day simple moving average is $31.21 and its 200 day simple moving average is $32.43. NewAmsterdam Pharma has a one year low of $23.05 and a one year high of $42.21. The company has a market cap of $3.23 billion, a PE ratio of -12.79 and a beta of 0.10.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $2.83 million. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 105,000 shares of the stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the completion of the sale, the chief accounting officer owned 24,353 shares of the company’s stock, valued at approximately $738,870.02. This represents a 81.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders have sold 210,000 shares of company stock worth $6,713,550. Corporate insiders own 12.74% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

Large investors have recently modified their holdings of the company. Farther Finance Advisors LLC raised its stake in NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after buying an additional 708 shares during the last quarter. Wells Fargo & Company MN boosted its position in NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after acquiring an additional 300 shares during the last quarter. KBC Group NV acquired a new stake in NewAmsterdam Pharma during the 1st quarter worth about $37,000. Navalign LLC acquired a new stake in NewAmsterdam Pharma during the 4th quarter worth about $46,000. Finally, Empowered Funds LLC bought a new position in shares of NewAmsterdam Pharma in the 4th quarter worth about $85,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.